Edition:
United States

Histogenics Corp (HSGX.OQ)

HSGX.OQ on NASDAQ Stock Exchange Capital Market

2.35USD
24 May 2018
Change (% chg)

-- (--)
Prev Close
$2.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
17,737
52-wk High
$3.26
52-wk Low
$1.60

Chart for

About

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company's product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $67.13
Shares Outstanding(Mil.): 28.69
Dividend: --
Yield (%): --

Financials

  HSGX.OQ Industry Sector
P/E (TTM): -- 28.62 32.94
EPS (TTM): -1.22 -- --
ROI: -183.10 13.26 12.79
ROE: -- 14.99 14.67

BRIEF-Perceptive Advisors LLC Reports 8.8 pct Passive Stake In Histogenics As Of Jan. 17

* PERCEPTIVE ADVISORS LLC REPORTS 8.8 PERCENT PASSIVE STAKE IN HISTOGENICS CORP AS OF JANUARY 17, 2018 - SEC FILING‍​ Source text - (http://bit.ly/2GlVfLJ) Further company coverage:

Jan 26 2018

BRIEF-Histogenics Announces Pricing Of Underwritten Registered Direct Offering

* ANNOUNCES PRICING OF UNDERWRITTEN REGISTERED DIRECT OFFERING OF 2,340,430 SHARES OF COMMON STOCK

Jan 22 2018

BRIEF-Histogenics And Medinet Enter Licensing Agreement For Commercialization Of NeoCart In Japan

* HISTOGENICS CORPORATION AND MEDINET CO., LTD ENTER INTO LICENSING AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NEOCART FOR THE JAPANESE MARKET

Dec 21 2017

BRIEF-MEDINET signs license contract for NeoCart with Histogenics

* Says it entered into a license contract for development and sale of autologous cultured chondrocyte named NeoCart, with Histogenics Corp

Dec 21 2017

Earnings vs. Estimates